This stock is screaming "turnaround story"! 📈 All these patents and FDA clearances are building serious momentum, but the market's still sleeping—RSI is deeply oversold. That volume spike on the 25th? Someone's starting to listen. This feels like a coiled spring. Strong BUY for the bold. #DiamondInTheRough

"Nuwellis is buzzing! 🐝 New CEO, fresh patents, and a $5M cash injection—this medtech underdog is flexing. The stock just exploded (hello, 25.95 high!), but RSI’s at a comfy 56—room to run. Volume? Skyrocketing. Chart’s wild, but that 9-period EMA just leapfrogged the 21-day. Bullish crossover alert! 🚦 News + momentum = BUY. Just buckle up—this ride’s got volatility written all over it. #MedtechMoonshot"

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Nuwellis, Inc. NUWE: 2.47 USD

Bullish views